Posted by Michael Wonder on 15 Mar 2018
Proposal to fund denosumab for osteoporosis
16 March 2018 - PHARMAC is proposing to fund denosumab (Prolia) injections from 1 June 2018 for the treatment of severe, established osteoporosis subject to certain clinical criteria being met.
Certain patients with severe, established osteoporosis who have received inadequate benefit from oral treatments and for whom zoledronic acid is contraindicated due to renal impairment would be eligible for funded treatment with denosumab.
PHARMAC received an application in 2012 to fund denosumab (Prolia) from the supplier, Amgen.
The application was reviewed on a number of occasions by both the Pharmacology and Therapeutics Advisory Committee (PTAC) and its Endocrinology Subcommittee. The final recommendation of PTAC was to fund denosumab for the treatment of osteoporosis in postmenopausal women who have received inadequate benefit from oral treatments and for whom zoledronic acid is contraindicated due to renal impairment, with a medium priority subject to certain criteria.
